Suven Life Sciences credit ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
−337−337−60.0−240−231
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−0.57×−0.57×−0.55×−0.89×−0.61×
0.92×1.19×0.36×1.87×1.83×
−1,838.51×−1,838.51×−3,682.30×−849.16×−458.07×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SUVEN₹264.20

Suven Life Sciences Limited

· Pharma & Health
₹ CrorePeersVIMTALABSTAKEMcap ₹6,967 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Net Debt-230.6-239.9-60.0-337.5-337.5
Net Debt/Equity-0.61-0.89-0.55-0.57-0.57
Net Debt/EBITDA1.831.870.361.190.92
Interest Coverage (EBIT/Interest)-458.07-849.16-3,682.30-1,838.51-1,838.51
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.